Good day and thank you for standing by. Welcome to the Bavarian Nordic 2023 Annual Report Conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rolf Sørensen. Please go ahead. Yeah, thank you, Operator. Welcome to Bavarian Nordic's full-year presentation, which was an extraordinarily strong result. My name is Rolf Sørensen, VP Investor Relations, and to go through the results, I have President and CEO Paul Chaplin and Executive Vice President and CFO Henrik Juuel. Before we start the presentation, I just want to quickly run through the forward-looking statements. This presentation includes forward-looking statements that involve risks, uncertainties, and other factors that are outside our control that could cause actual results to differ from the results discussed. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year, as well as statements concerning our plans, objectives, goals, future events, performance, and other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. So with this, I will hand over the first part of the presentation to you, Paul. Yep, thank you, Rolf, and welcome everyone to the call today. Just turn to slide five. As Rolf said in the introduction, we've announced the annual results for last year, and it was a tremendous year in terms of our financial performance, and it's a record year in the history of Bavarian Nordic. So we've recorded more than DKK 7 billion in revenue, which is obviously $1 billion. That is a performance that is due to the flawless execution of our commercial strategy, strong brand performance, and a resurgence in travel in our travel health portfolio, and record sales in our public preparedness, primarily due to strong performance in the base business but also a surge in orders following the unprecedented outbreak of mpox or monkeypox, which started in 2022. So record revenues and record profits at DKK 2.6 billion, which represents a 37% EBITDA margin. So as I said, an outstanding result and really due to a very strong commercial performance across the portfolio. If you look on the right-hand side, before 2020, we really only had one product for two indications. That was JYNNEOS. That's our smallpox and mpox business. It's a profitable business but was primarily government sales to two customers, the U.S. government and Canada. And if you look at the graph that shows you in 2019, we were a sub-DKK 1 billion revenue company with this one product. We took the decision in 2019 to commercialize the business and add more commercial assets, and that started in 2020 with the acquisition of the rabies and TBE from GSK. At that time, we thought that in our hands, we could grow these assets and we could make them perform better than in the previous owner's hands because we would have a stronger focus on these assets. As you can see, in 2021, despite the fact that we had headwinds due to the COVID pandemic, which obviously devastated international travel, we still added to the revenue, generating a company with a DKK 2 billion top-line. What we've seen in 2022 and 2023 is a resurgence in travel coming out of the pandemic. In fact, this year or last year, we sold more doses of rabies and TBE than anyone else before, which is really a strong endorsement of that initial strategy that we could take over assets that were not receiving the focus that they required and in our hands could turn them around and actually grow the market share and sell more doses than anyone else before. We added to this portfolio last year in 2023 with the acquisition of the cholera and typhus vaccine, and this now, together with third-party sales, represents the largest travel vaccine portfolio in the globe. You can also see in the public preparedness that there's been steady growth in 2021 but particularly in 2022 and 2023, and this is primarily due to a surge in orders due to the, as I said, unprecedented mpox outbreak that started in 2022. We've actually supplied in 2022, 2023, more than 15 million doses to more than 70 countries worldwide. No country that's asked for doses was turned away. But this, of course, has led to record sales in 2023, which I'll Henrik Juuel address in more detail, but it's approximately DKK 5 billion in sales in 2023. This essentially was not going to be sustainable as obviously the number of cases of mpox is declining, in part due to the high efficacy associated with the use of JYNNEOS. However, coming out and what was guided for 2024 is now between DKK 5 billion and DKK 5.3 billion in revenue, and that in part is because we now have more customers in public preparedness and our new base business. We have a new solid base business that I'll get to in the coming slides that is really projecting us together with our travel health as a DKK 5 billion revenue company with ambitions to have an EBITDA margin between 25%-30% moving forward. So if we go to the next slide, slide six, so where are we going from here? We've obviously come a long way in our commercial journey, but moving forward, we want to build on our position and become a pioneering force in vaccines, and we want to expand our reach and impact by getting more access to our life-changing vaccines. To achieve this, we have two strategic tracks. One is to deliver continued growth. One is to expand and drive our travel health business, which I'll come to. The other is, as I said, we have a new base business in public preparedness, but we believe there are numerous opportunities to continue to grow that business and see additional orders from other governments. In addition to this organic growth, which I'll talk to in the coming slides, M&A will remain a key part of the strategy moving forward. It has successfully allowed to transform the company with two acquisitions since 2020, and it will be a key part moving forward to really grow the business and have bolt-on acquisitions that will allow us to increase the top-line and the profitability moving forward. The other strategic track is to bring innovative solutions to two main areas. One is to secure reliable supply. Production of vaccines is complicated. It's challenging. We have a very good track record. However, the growth story that I'll walk you through really demands that we even have an improved focus on our ability to supply and improve our manufacturing processes and distribution. The other area is in R&D, which is split into two main components. When you have a commercial portfolio, it doesn't stop when the products are approved. You have to continue to look and look after those commercial assets, looking whether you can expand the population that it's recommended for, look at improvements in manufacturing that not only improves the efficiency of production but also, from a sustainability point of view, uses less energy, or whether there are more formulations or different formulations that could improve the assets. Of course, the other part of R&D is to look at innovation to bring new assets through research centers that we have in Munich and Denmark and in the U.S. into the pipeline. So if you go to slide seven, to talk a little bit more about the travel health and how we're going to grow that business, well, between now and 2027, we see strong growth, double-digit growth year-on-year. And how we're going to achieve that really depends on which products we're talking about. So if we talk about the TBE and rabies, which we acquired in 2020, as I said, we've taken those assets a really long way already with record sales recorded last year. We believe that, again, with the strong brand performance, there is still more growth to attain, and obviously, travel continues to grow. More people are traveling, and more people are traveling to exotic destinations where they need to be vaccinated. Thirdly, we're looking to expand our commercial footprint. Our original model was to focus in certain territories such as the U.S. and Germany but to rely on third parties to distribute in other territories. As we now have more commercial assets, we can change that strategy and start to look at expanding into those other territories. This year, we'll be expanding into the U.K. and Canada, and in the following years, we'll be expanding to other territories in Europe, intensifying and expanding our commercial footprint. In terms of cholera and typhoid, these essentially were removed from the market by their previous owners during COVID, so they're not being present on the market. They're great assets in that they're oral vaccines, which our market research shows people prefer, but we essentially have to relaunch these assets this year. In the coming years, we believe we can take the combined revenue of these two assets to $100 million annually in the next few years. Thirdly, we have a Chikungunya vaccine candidate. The phase 3 is read out successfully last year, really showing that we have a differentiated candidate, and we're filing for approval during this year with a view that we will launch in both the U.S. and Europe in 2025. We really see this as an exciting opportunity, not only as an addition to our portfolio but to really grow the business. Chikungunya is a devastating disease spread by mosquitoes, and until last year, there was really no vaccine available. We are differentiated in terms of safety. We have an improved safety profile, which we believe will come through and be obvious when the product is approved. It has also a very fast onset of action, meaning you can get protection within a week or two based on the immune markers agreed with the regulators. We believe we have the best-in-class asset, and we'll be launching shortly after our competitors that will launch this year. Great opportunities in the travel health to really grow the business and move it forward. Turn to the next slide, slide eight, public preparedness. As I said, historically, this is how Bavarian Nordic built itself. We have a longstanding and successful partnership with the U.S. government. Together, we have developed JYNNEOS as a safer alternative smallpox and mpox vaccine, and we have secured funding in excess of $2 billion over the last decade or so. With public preparedness, one of the historical challenges, particularly with very few customers, is that it is rather lumpy in nature, difficult to predict, and that is one of the drivers for commercializing and bringing on the travel health business. What we've seen in the last two years, however, is during the mpox outbreak, obviously, many more customers, a surge in orders. As we come out of that mpox outbreak, we now have more customers than we did historically. So we have a handful of customers where we have existing contracts and expect new orders. And for that reason, we believe we can firm up our base business in public preparedness. It's between DKK 1.5 billion and DKK 2 billion year-over-year. This year, as part of the guidance that Henrik will get to, we're actually guiding DKK 3 billion, so more than the base business. That in part is because we anticipate more orders that are currently not contracted. Secondly, there is a private market that has emerged following the Mpox outbreak. So in the U.S., there's a recommendation to vaccinate risk populations, which represent about 2 million individuals, and we'll be launching this year. So that business, which is emerging, is on top of the base business. In addition to that, we are in concrete discussions with a number of governments that, following the Mpox outbreak, are concerned about orthopox viruses, whether it's Smallpox or Mpox, and are talking about stockpiling. And this will lead to additional orders or lumpy orders over that base business. And as and when that occurs, it could easily project our revenues back to the 2023 numbers we've reported today. So before I hand over to Henrik, I'll just sum up, really. We have come an awful long way in the last three years. We've transitioned from an R&D-focused company with one commercial asset contracted to one or two governments around the world to a company that has a fully integrated manufacturing and distribution worldwide and a very, very attractive underlying business based on the largest travel vaccine portfolio and an attractive public preparedness business. Moving forward, we see lots of opportunities for organic growth, whether it's relaunching some of the assets we purchased last year, launching a brand new asset for Chikungunya in 2025, or growing the existing business from a strong performance that we've demonstrated in 2023. In terms of R&D, we have a focused strategy on really infectious diseases but also improving our commercial assets. There are opportunities near-term to really solidify the profitability position. As I said, we have an ambition to have an EBITDA margin of 25%-30%. In the near term, there are many opportunities to actually grow that margin. Some is on improving our manufacturing processes. One in particular is to complete the tech transfer of our Rabies and TBE that will have a significant impact in the profitability of those assets. We have generated a profitable company that's one of the largest pure-play vaccine companies in the globe. The profits will allow a very strong cash flow in the coming years that will allow us to invest back into the business or look at M&A opportunities as and when they arise. With that, I'll hand over the presentation to Henrik Juuel. Thank you very much, Paul. So as Paul already said, 2023 was, in financial terms, a record year, delivering results never seen in the history of Bavarian Nordic before, obviously driven by extremely strong revenue performance. So why not start there on slide 11? We delivered more than DKK 7 billion in revenue, DKK 7 billion and 62 million to be precise. And that was, of course, driven by very strong sales performance in the Q4. We knew we were going to have a busy Q4 when we reported the nine-month numbers in order for us to deliver on the guidance that we had put forward to the market. And we are very, very happy that we delivered nearly DKK 2.5 billion in revenue for the Q4 alone. That was driven by continued strong performance within our Travel Health business but, of course, also by the execution on the mpox, Smallpox orders we got related to the mpox outbreak that started back in 2022. So very strong revenue and sales numbers. And if you look at the column to the right, you will see that the growth has been significant across the entire portfolio. Our Rabies business grew by 32%, our TBE business by 40%, and our Public Preparedness business by 190%, driven by the surge in orders from the mpox outbreak. So very, very strong revenue performance in 2023 and, in particular, in the Q4 of last year. On the next page, I spent a little time looking into some of the important parts of the business. If we start with the Rabies business first, again, record year with numbers exceeding any prior owner's results. A testimony to the fact that our strategy has worked, providing dedication and focus to these products has really made a difference. We have seen the Rabies business grow by 32%, as I showed on the previous slide, and that has been driven by a mix of strong brand performance but also very strong market growth. We saw 25% market growth in the U.S. and 87% market growth in Germany, where the product is a pure traveler's vaccine and has been significantly impacted by the rebound of traveling. And if you look at these markets after the tremendous growth we saw in 2023, we can see that, actually, in the U.S., the market size is already more than 40% larger than pre-COVID. So a significant market growth, a market that is much larger than what we saw previous COVID and when we took over the vaccine. Same goes for Germany, not to the same extent, though, but we do see a market that is now, today, 6% larger than what we saw in 2019 pre-COVID. Strong brand performance demonstrated by a 70% market share in the U.S. and 93% in Germany. As you will see on the graph, we saw a 9% dip in revenue in the Q4 2023 compared to prior year. But overall, the year grew by 32%, and I think this dip, I think, is simply due to some of the, you can say, variability between the seasons across the year. So very, very strong growth on a full-year basis. On slide number 13, our TBE sales, we delivered a very, very good 40% growth in revenue on a full-year basis, driven by steady growth quarter by quarter, basically, and a strong market growth in our key market, Germany, 33% growth, again demonstrating that, right now, the market is larger than pre-COVID, 12% growth compared to 2019 levels. So strong market growth. On slide number 14, you will see the impact of the significant revenue growth we saw. So full-year basis, DKK 7,062 million in revenue. We are looking at operating costs of a little more than DKK 3 billion impacted by the write-down of the COVID-19 assets. That's DKK 558 million, approximately, and then also impacted by the closure of the RSV project. It's impacted by increased commercial activity and, of course, by the recent acquisition that basically impacts both R&D but also our SG&A costs to some extent. It's a strong EBITDA. You see DKK 2.6 billion corresponding to an EBITDA margin of 37%. Please bear in mind here that the COVID-19 write-down is not impacting our EBITDA number here. If you look further down, the P&L, we also have a very positive EBIT, DKK 1.5 billion, and even at a net profit level, we are close to DKK 1.5 billion in Danish kroner, which is up from a loss of DKK 347 million in 2022. So truly record numbers never seen in the past for Bavarian Nordic. On slide 15, just a quick look on our cash flow and some selected balance sheet numbers. And if we start to the left, cash flow from operating activities was positive by DKK 1.1 billion, of course, very positively impacted by the strong earnings during the year, which actually managed to more than compensate for a higher level of net working capital driven by the planned inventory increases and the very, very high level of accounts receivable we saw at the end of 2023 due to the high Q4 sales. Cash flow from investment activities, minus of DKK 946 million. It's driven by the acquisition we did from Emergent BioSolutions that we closed in May 2023 and additional milestones that we have paid as well to GSK and then partly offset by divestments of securities that we have done during the year. Cash flow from financing is impacted by the capital increase we did in connection with the acquisition. It's impacted by COVID-19 funding and then a repayment of a Repo position that does no longer exist. Adding all of that up actually shows a positive net cash flow for a period of close to a billion, DKK 909 million. So a strong cash flow for 2023. And if you look to the right, that brings us in a solid position with nearly DKK 1.9 billion in securities, cash, and cash equivalents. We have no real debt at the moment. We have DKK 17 million as a mortgage loan. That's all. We do have a revolving credit facility with our banks of DKK 1 billion, but we have not drawn anything down on that facility yet. So very strong cash position. On the next slide, just wanted to enter the guidance for the year. Let me see where did that slide go? I can't find it here. I'm just looking for that. Okay. So guidance for 2024, as we have communicated, revenue between DKK 5 billion and DKK 5.3 billion, consisting of approximately DKK 2.1 billion from our Travel Health business that corresponds to an anticipated 12% growth over 2023. And then in our Public Preparedness business, we are guiding between DKK 2.7 billion and DKK 3 billion above our base business, as Paul alluded to. We are taking a different approach in terms of our guidance within the Public Preparedness business this time. In the past, we used to guide only on revenue secured by contracts. As we only had one or two customers at the time, now, today, we have a much broader customer portfolio, which enabled us to go out and estimate the range of revenue we could anticipate for the full year. To date, as we speak here, we have secured DKK 1.6 billion, approximately, out of the DKK 2.7 billion-DKK 3 billion that we are guiding for the full year. We are anticipating to spend approximately DKK 850 million in R&D in 2024, and nearly half of that goes towards the development of Chikungunya, where we still anticipate to file for the licensure both in Europe and in the U.S. this H1 of year of 2024. One thing I need to mention here is that our guided numbers, we are including manufacturing Chikungunya vaccines that eventually could be sold once we have an approved vaccine. The value of those corresponds to approximately DKK 240 million, and they are expensed in our guidance. Pending approval of the vaccine, that expenditure will be reversed, and it has an impact of 5 percentage points, approximately. So if we adjust for that, then the implicit EBITDA margin that we are guiding here is actually between 27%-30% for 2024. So if we look to the right, we are looking a little further ahead and talking about our ambitions from 2024 and up until 2027. Here, we are guiding that we are expecting continued double-digit growth within our travel health business, 10%-12%. As Paul alluded to, we are expecting that the value of our base business, which consists of our, you can say, repeat customers, the larger customers with commitments beyond one year, we are expecting revenue to be between DKK 1.5 billion-DKK 2 billion. That is excluding any potential spikes driven by new outbreaks, or it could also be the odd government placing orders to replenish their stocks over time. That is just the base that we will expect from the public preparedness side of the business. We have an ambition to deliver an EBITDA margin of 25%-30%, and that has to be seen in light of the public preparedness base business that we are talking about here. It is clear that if there is an outbreak or spike, whatever, business on top of this, that will have a relatively larger impact on our EBITDA margin. That is also one of the reasons that we saw a 37% EBITDA margin in 2023. Capital allocation, I think, short term, I think we will focus on our commitments to pay back milestones to GSK and Emergent BioSolutions. We still owe them approximately DKK 2.6 billion. But by mid-2025, that's not far from here. That will all be behind us. So we have to pay these DKK 2.6 billion within the next year. Now, it's less than 1.5 years. It's 5 quarters, basically, left to pay those milestones. So that's our priority number one. Then, of course, we will continue to invest to grow our current business and our pipeline. And eventually, this will lead to increased cash flow generation. It will give us expanded financial flexibility, for instance, getting access to better debt financing, which eventually will allow us to, you can say, be a bit more aggressive on synergistic M&A and eventually consider returning money back to the shareholders as well. So with that, I will give the word back to the operator and open up for questions. Thank you. As a reminder, to ask a question, you will need to press star one and one on your telephone and wait for your name to be announced. To withdraw your question, please press star one and one again. Please stand by while we compile the Q&A queue. One sec. Sorry. Our first question comes from the line of Thomas Bowers from Danske Bank. Please go ahead. Your line is open. Yes. Thank you very much. Just one question from my side here, just on the margin guidance. So you were saying that you have around 5 percentage point negative impact from Chikungunya this year. I'm just wondering, why would we expect margins from 2025 until 2027 to actually be lower than this year if you remove the impact from Chikungunya? Is that the mix impact from expected lower mpox revenue? And then, of course, you should have some tailwinds from travel health. So maybe help me understand how you get to the low end of that long-term guidance. I think the main reason, Thomas, and first of all, thanks for the question here. I think that is, remember what we are guiding for 2024 is beyond our base business within public preparedness. We are guiding DKK 2.7 billion-DKK 3 billion. So you can say, in the upper end of that, it's actually more than DKK 1 billion, more than our base business. That will have a positive impact on the EBITDA margin, of course. And if we then adjust for the Chikungunya, that also brings us to the upper end of the guidance, 27%-30% EBITDA margin for 2024. So I think it's very important when we look at the EBITDA margin, it's extremely sensitive, of course, to the revenue and in particularly to the potential spike business opportunities within public health preparedness as the orders typically come. Without necessarily putting a lot of sales marketing, promotional efforts behind it, it's a few people working with governments, basically. So that part of the business is extremely impactful on our EBITDA margin. So I hope I answered your question, Thomas. Yes. Thank you. Then just to follow up, just sort of a reminder here. So on the freeze-dried BLA, it's been somewhat delayed. I know there's some dialogue with BARDA. Can you maybe just update us on where we are here also in regards to how much you sort of bake into the full year 2024 numbers for the initial milestones from the $299 million contract with the freeze-dried in that vein? So yeah. Thank you. Yeah. So hi, Thomas. So as you said, the current freeze-dried order is $299 million. And I've just got to get my years right. I think in 2022, BARDA issued $120 million of that for manufacturing the initial doses for freeze-dried. That essentially is part of the revenue guidance that we've included in 2024 this year. So the remainder of the $299 million is hopefully coming from BARDA in the coming years. In terms of the regulatory path, we are filing for the supplemental BLA later this year, meaning the approval should occur next year. That is not conditional on the remainder of that 299 because that's all going to happen or a lot of the manufacturing will occur before the approval is actually awarded. Okay. So I guess given that you actually are about to file this year, it does mean that you also have sort of a framework for how we should see orders coming in the sort of longer term. I guess, of course, you wanted to be reassured that it wouldn't be a sort of a blow to your future P&L if you were actually to advance into the freeze-dried. So exactly. So we have one order, 299, and that will be spread over partly as part of our guidance in 2024. We'll see the remainder in 2025 and a bit in 2026. And then hopefully, we will be seeing, post-approval, additional orders on top, obviously, from BARDA. Yeah. Okay. But you don't have any idea on sort of the level of number of doses that could be in the future stockpile? So you just have sort of reassurance that it's definitely going to be a higher number than what you have seen historically? Well, yeah. So I mean, the two numbers that are out there publicly, 20 million doses prior to approval and 133 million doses post-approval. So those are the two numbers that are out there. Of course, as I've said several times, I think we shouldn't anticipate one big, large order. That's not how it's going to work, most likely. So we will see incremental orders annually leading up to the stockpile that they want. But as I said, the only public numbers that are out there are those two, so 20 or in excess of 100 million doses. Okay. Okay. Great. Thank you very much. Thank you. Once again, to ask a question, you will need to press star one and one on your telephone and wait for your name to be announced. To withdraw your question, please press star one and one again. Please stand by while we wait for further questions. There are no further questions at this time, so I'll hand the call back to Paul Chaplin for closing remarks. Yeah. Thanks, everyone. Thanks for the time joining the call and for the questions. Have a great day. Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect. Speakers, please stand by.